We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00854945
Recruitment Status : Completed
First Posted : March 3, 2009
Last Update Posted : June 26, 2017
Sponsor:
Information provided by (Responsible Party):
Onconova Therapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : September 2013
  Study Completion Date : February 2014
  Certification or Request for Extension to Delay Results Submission: October 3, 2014
Publications:
Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.